| payload |
{"created_at":"2026-04-21T03:09:54.871 {"created_at":"2026-04-21T03:09:54.871544+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:9a7ffde80e8162bd","evidence_event_ids":["evt_7d3f18437a6c"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","as_of":"2026-04-21T03:09:54.871544+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","company":"SPRUCE BIOSCIENCES, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_ae8c48305884cebe","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","content_type":"text/plain","enriched_at":"2026-04-21T08:55:06.522077+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B5","final_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt","source_event_id":"evt_7d3f18437a6c","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"e068aa521ff9312e","kind":"sec_filing","published_at":"20260420","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-20","2026-04-17","2025-10-29","2026-04-21"],"entities":[{"asset_class":"equity","name":"Spruce Biosciences, Inc.","relevance":"high","symbol":"SPRB","type":"issuer"},{"asset_class":"exchange","name":"Nasdaq Capital Market","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"other","name":"Leerink Partners","relevance":"low","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Guggenheim Securities","relevance":"low","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Oppenheimer & Co.","relevance":"low","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Jones","relevance":"low","symbol":"","type":"co-manager"},{"asset_class":"other","name":"Craig-Hallum","relevance":"low","symbol":"","type":"co-manager"}],"event_type":"listing","information_gaps":["What changed vs prior known state is not provided in the signal; only the current 424B5 content is available.","The number of shares being offered (common stock and/or pre-funded warrants) is not specified in the provided text (placeholders present).","Delivery date is shown as a blank placeholder (\u201con or about , 2026\u201d).","Underwriting option details include blanks for the additional number of shares and the dollar amounts for underwriting discounts/commissions and total proceeds.","No explicit description of use of proceeds, offering size, or final pricing is included in the provided excerpt beyond the pre-funded warrant pricing formula."],"key_facts":["Form 424B5 was filed pursuant to Rule 424(b)(5) for Registration No. 333-291152.","The preliminary prospectus supplement is dated April 20, 2026 and relates to a prospectus dated October 29, 2025.","The offering includes shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.","The purchase price of each pre-funded warrant equals the public offering price per share of common stock minus $0.01.","Each pre-funded warrant has an exercise price of $0.01 per share.","The filing states there is no established public trading market for the pre-funded warrants and the issuer does not expect one to develop; the issuer does not intend to apply for listing of the pre-funded warrants.","SPRB common stock is listed on the Nasdaq Capital Market under symbol \u201cSPRB.\u201d","The last reported sale price of SPRB common stock on April 17, 2026 was $70.30 per share.","The filing states the issuer is a \u201csmaller reporting company\u201d and elected to comply with reduced public company reporting requirements.","The filing includes an underwriters\u2019 option for 30 days to purchase up to an additional unspecified number of shares at the public offering price, less underwriting discounts and commissions.","The filing includes placeholders for delivery date and amounts for underwriting discounts/commissions and total proceeds (not filled in the provided text)."],"numeric_claims":[{"label":"pre-funded warrant exercise price ($/share)","value":"0.01"},{"label":"pre-funded warrant purchase price adjustment ($)","value":"0.01"},{"label":"SPRB last reported sale price (Apr 17, 2026)","value":"70.30"},{"label":"underwriters\u2019 option period (days)","value":"30"}],"primary_claim":"SPRB filed a Form 424B5 preliminary prospectus supplement dated April 20, 2026 for an offering of common stock and pre-funded warrants with a $0.01 exercise price per pre-funded warrant.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Spruce Biosciences, Inc. filed a Form 424B5 preliminary prospectus supplement for an offering of common stock and pre-funded warrants. The filing describes pricing mechanics, warrant exercise terms, and notes there is no established trading market for the pre-funded warrants.","topics":["SEC filing","registration statement","pre-funded warrants","common stock offering","Nasdaq listing","underwriting option","risk factors"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 SPRUCE BIOSCIENCES, INC. \u00b7 Filed 20260420","ticker":"SPRB","tickers":["SPRB"],"title":"SPRB filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-163919.txt"}}... |